People and Places in the News
- By BSTQ Staff
Sanofi-aventis has signed a binding agreement to acquire Fovea Pharmaceuticals SA, a privately held French research and development biopharmaceutical company focused on ocular diseases.
The CSL Behring-Canada Research Chair in Endothelial Cell Biology has been established to research and develop new therapies for patients with bleeding and immune system disorders. The chair program is a professorship created through the Canada Research Chairs Program, and will be held by the newly appointed director of the CBR, physician-scientist Edward Conway, MD, PhD, MBA.
Human Genome Sciences (HGS) received a $75 million milestone payment from Novartis on successful completion of Phase III development with the chronic HVC drug albinterferon alfa2b and the decision to submit regulatory approval applications. The drug (formerly known as Albuferon), a genetic fusion of human albumin and interferon alfa generated using HGS’ albumin-infusion technology, will be called Zalbin in the U.S. and Joulferon in the rest of the world.